Azenta reiterates 2025 guidance with 3-5% organic growth and EBITDA margin expansion
Seeking Alpha News (Wed, 5-Feb 2:33 PM ET)
Azenta’s Promising Growth and Strong Financial Performance Lead to Buy Rating
TipRanks (Wed, 5-Feb 12:35 PM ET)
Here are the major earnings after the close today
Seeking Alpha News (Wed, 5-Feb 10:00 AM ET)
Azenta beats Q1 top-line and bottom-line estimates; reaffirms FY25 outlook
Seeking Alpha News (Wed, 5-Feb 7:18 AM ET)
Azenta Reports First Quarter Results for Fiscal 2025, Ended December 31, 2024
PRNewswire (Wed, 5-Feb 7:00 AM ET)
Top Executive Sells Azenta Shares in Noteworthy Transaction
TipRanks (Tue, 4-Feb 9:02 PM ET)
Here's the major earnings before the open tomorrow
Seeking Alpha News (Tue, 4-Feb 6:00 PM ET)
Azenta Q1 2025 Earnings Preview
Seeking Alpha News (Tue, 4-Feb 1:06 PM ET)
Azenta Announces the Election of Dipal Doshi to its Board of Directors
PRNewswire (Thu, 30-Jan 4:05 PM ET)
Azenta Announces Fiscal 2025 First Quarter Earnings Conference Call and Webcast
PRNewswire (Mon, 27-Jan 4:05 PM ET)
Azenta Inc is a provider of life sciences solutions, enabling impactful breakthroughs and therapies to market faster. It provides a full suite of reliable cold-chain sample management solutions and genomic services across areas such as drug development, clinical research and cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. The company has three reportable segments that are Sample Management Solutions, Multiomics, and B Medical Systems. It generates a substantial part of its revenue from its Sample Management Solutions segment.
Azenta trades on the NASDAQ stock market under the symbol AZTA.
As of February 5, 2025, AZTA stock price climbed to $53.76 with 785,988 million shares trading.
AZTA has a beta of 0.65, meaning it tends to be less sensitive to market movements. AZTA has a correlation of 0.06 to the broad based SPY ETF.
AZTA has a market cap of $2.46 billion. This is considered a Mid Cap stock.
Last quarter Azenta reported $170 million in Revenue and $.18 earnings per share. This beat revenue expectation by $462,000 and exceeded earnings estimates by $.08.
In the last 3 years, AZTA traded as high as $93.39 and as low as $36.01.
The top ETF exchange traded funds that AZTA belongs to (by Net Assets): IJR, VTI, VB, VXF, VBR.
AZTA has underperformed the market in the last year with a price return of -18.7% while the SPY ETF gained +23.7%. However, in the short term, AZTA had mixed performance relative to the market. It has outperformed in the last 3 months, returning +19.7% vs +6.4% return in SPY. But in the last 2 weeks, AZTA shares have been beat by the market, returning -0.1% compared to an SPY return of +0.2%.
AZTA support price is $50.78 and resistance is $53.16 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AZTA shares will trade within this expected range on the day.